Recent Company News

• 04:04 AM ET Oct 07, 2026
  

  Otsuka unit completes rolling submission of supplemental BLA to FDA for VOYXACT (¥11475.0000, 0)

• 07:37 PM ET Oct 01, 2026
  

  Taiho pharmaceutical initiates NDA submission to the FDA for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC (¥11465.0000, 0)

• 05:51 AM ET Sep 28, 2026
  

  Otsuka Holdings upgraded to buy from outperform at Daiwa (¥11080.0000, 0)

• 08:27 AM ET Sep 22, 2026
  

  Otsuka's ulefnersen meets primary endpoint in phase III FUS-ALS trial (¥11120.0000, 0)

• 11:23 PM ET Sep 15, 2026
  

  Quick Take - Otsuka Holdings trading lower (5.5%); Vera's Trutakna data seen broadly competitive though Voyxact positioning seen holding (¥10800.0000, -625)

• 11:19 PM ET Sep 15, 2026
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:57 PM ET Sep 15, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:28 PM ET Sep 13, 2026
  

  Cullinan Therapeutics reports results from Phase 3 REZILIENT3 trial presented at IASLC ($20.59, 0.00)

• 01:27 AM ET Aug 19, 2026
  

  IRLAB Therapeutics's Parkinson's drug candidate IRL757 receives WHO generic name Linepemat (SEK 1.74, 0.00)

• 05:44 PM ET Aug 13, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market